Transforming Disease Detection

Miroculus was a San Francisco-based biotechnology company that disrupted the medical industry and life science with its innovative approach to disease detection. Through its portable lab, Miroculus enabled thousands of scientists, engineers, hospitals and lab operators all over the world to create, share, download and run the most complex protocols and tests in a fully automated fashion. Miroculus created a special technology that automates and simplifies complex genetic processes, like preparing DNA for analysis, in a small, easy-to-use machine. This makes tasks like studying genes or editing cells faster and more efficient. Miroculus IP extended to over 25 patent applications within 13 different patent families. The company raised over $45 million during its operations and successfully exited to Integra, where Fay Christodoulou is now Chief Scientific Officer.

Miroculus in Three:

• What problem did Miroculus solve? Miroculus addressed the need for efficient and automated disease detection in the medical and life sciences.

• What was innovative about Miroculus? Miraculous' Miro technology utilized digital microfluidics to automate and miniaturize complex genomic protocols, allowing DNA preparation analysis to be analyzed easier.

• Who used Miroculus? Thousands of scientists, engineers, hospitals, and lab operators worldwide, including those in the USA, Canada, UK, France, Germany, Austria, Sweden, Switzerland, Japan, and China, used Miroculus's portable lab.

The company has raised funds higher than 39$ million from venture capital firms (OSFund, Nazca), family offices, and companies on the Fortune 500 list. In 2018, Miroculus was co-financed by Endeavor Catalyst as well and recently closed its Series B financing round amounting to 45$ million, with Cota Capital and Section 32 participating in the expansion of financing, aiming at the market exit of its impressive Miro Canvas device. In 2023, the company was acquired by Integra Biosciences.